1 486 patients treated for Actinic Keratosis, across five separate trials, and 138 patients treated for Basal Cell Carcinoma (CT008) in a single trial, totalling 624 patients treated in phase III Ameluz® trials.
Trial ALA-AK-CT002
Trial name: Photodynamic therapy with BF‐200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer‐blind phase III study in comparison with a registered methyl‐5‐aminolaevulinate cream and placebo.
Disease treated: Actinic Keratosis | Treatment used: Ameluz® | Number of patients: 248
Reference: Dirschka T, Radny P, Dominicus R, Mensing H, Brüning H, Jenne L, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: Results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. British Journal of Dermatology. 2011 Dec 21;166(1):137–46.
Trial ALA-AK-CT003
Trial name: Photodynamic therapy with BF‐200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double‐blind, placebo‐controlled phase III study.
Disease treated: Actinic Keratosis | Treatment used: Ameluz® | Number of patients: 81
Reference: Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka T, Krähn-Senftleben G, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: Results of a prospective, randomized, double-blind, placebo-controlled phase III study. British Journal of Dermatology. 2010 May 28;163(2):386–94.
Trial ALA-AK-CT007
Trial name: A randomized, double‐blind, phase III, multicentre study to evaluate the safety and efficacy of BF‐200 ALA (Ameluz®) vs. placebo in the field‐directed treatment of mild‐to‐moderate actinic keratosis with photodynamic therapy (PDT) when using the BF‐RhodoLED® lamp.
Disease treated: Actinic Keratosis | Treatment used: Ameluz® | Number of patients: 55
Reference: Reinhold U, Dirschka T, Ostendorf R, Aschoff R, Berking C, Philipp‐Dormston WG, et al. A randomized, double‐blind, phase III , multicentre study to evaluate the safety and efficacy of BF ‐200 ALA (AMELUZ®) vs. placebo in the field‐directed treatment of mild‐to‐moderate actinic keratosis with photodynamic therapy (PDT) when using the BF ‐rhodo LED® lamp. British Journal of Dermatology. 2016 June 25;175(4):696–705.
Trial ALA-AK-CT010
Trial name: Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk, and neck in a vehicle-controlled phase III study.
Disease treated: Actinic Keratosis | Treatment used: Ameluz® | Number of patients: 50
Reference: Ulrich M, Reinhold U, Dominicus R, Aschoff R, Szeimies RM, Dirschka T. Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk, and neck in a vehicle-controlled phase III study. Journal of the American Academy of Dermatology. 2021 Dec;85(6):1510–9.
Trial CT009_AK_DaylightPDT_
Trial name: A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis.
Disease treated: Actinic Keratosis | Treatment used: Ameluz® | Number of patients: 52
Reference: Dirschka T, Ekanayake-Bohlig S, Dominicus R, Aschoff R, Herrera-Ceballos E, Botella-Estrada R, et al. A randomized, intraindividual, non-inferiority, phase III study comparing daylight photodynamic therapy with BF-200 ala gel and MAL cream for the treatment of actinic keratosis. Journal of the European Academy of Dermatology and Venereology. 2018 Aug 14;33(2):288–97.
Trial ALA-BCC-CT008
Trial name: A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF‐200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy.
Disease treated: Basal Cell Carcinoma (CT008) | Treatment used: Ameluz® | Number of patients: 138
Reference: Morton CA, Dominicus R, Radny P, Dirschka T, Hauschild A, Reinhold U, et al. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy. British Journal of Dermatology. 2018 May 16;.
Total patients treated: 624